Oncolytic Adenovirus in Phase 1 has extended half-life TGF-ß trap LA JOLLA, Calif., December 8, 2021 -- EpicentRx, Inc., a clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other...
LA JOLLA, Calif., Nov. 22, 2021 -- EpicentRx, Inc., a clinical-stage biotechnology company at the forefront of oncolytic viruses and small molecules for the treatment of cancer and other inflammatory-driven diseases, today announced that the United States Patent and...
Cancer-targeting adenovirus enhanced with a TGFβ Trap well tolerated in patients with advanced cancer TORREY PINES, Calif., Sept. 29, 2021 -- EpicentRx Inc., a leading-edge drug and device company with cancer and inflammatory disease-targeted platforms, today...
Company secures 10M US dollar growth capital term loan from Silicon Valley Bank (SVB) to accelerate development of immunotherapies for cancer AdAPT-001, a TGF-beta trap expressing oncolytic virus, designed to activate the immune system and improve checkpoint...